Announcing a new article publication in BIO Integration. Gallbladder and biliary tract cancers (GBTCs) are highly lethal ...

Positive high-level results from the EMERALD-3 Phase III trial showed AstraZeneca's Imfinzi (durvalumab) in combination with Imjudo (tremelimumab ...

Gastroenterology focuses on diagnosing and treating disorders of the digestive tract and accessory organs to improve patient ...

The South Warwickshire University NHS Foundation Trust (SWFT) has marked a major clinical milestone with the completion of ...

A groundbreaking investigation has brought to light a notable association between high sugar intake and the risk of ...

Bristol Myers Squibb (NYSE: BMY) today announced data from a Phase 4 clinical trial evaluating the symptom stability, safety and tolerability of Cobenfy (xanomeline and trospium chloride) when ...

In September 2025, at the 2025 China Healthcare Decision-makers Conference (2025 CHDC) and the China Innovative Drug Decade Achievement Tour organized by Pharmcube, the Company was listed on the ...

In this study, researchers aimed to determine whether the addition of durvalumab to gemcitabine plus cisplatin increases time toxicity.

(Alliance News) - GSK PLC on Thursday said the US Food & Drug Administration approved Lynavoy for the treatment of cholestatic pruritus in patients with primary biliary cholangitis.

Gallbladder and biliary tract cancers (GBTCs) are highly lethal malignancies with a heterogeneous global burden. Most existing epidemiological studies have been regional and descriptive, and have ...

Advanced biliary tract cancer represents one of the most challenging gastrointestinal malignancies in China, with increasing incidence and extremely poor prognosis due to late-stage diagnosis and ...

Nagoya University researchers and their collaborators have found that minimally invasive laparoscopic surgery significantly reduces blood loss and improves jaundice recovery compared to traditional ...